HealthcareServices

Global Colorectal Cancer Molecular Diagnostics Industry Trends and Market Forecast 2026–2030

February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the colorectal cancer molecular diagnostics market from 2026–2035 with trusted insights from The Business Research Company

What market expansion outlook does the Colorectal Cancer Molecular Diagnostics Market show for the 2026–2030 period?

The colorectal cancer molecular diagnostics market has seen significant expansion in recent years. Its size is anticipated to rise from $2.78 billion in 2025 to $3.02 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.5%. Historically, this market growth has been propelled by factors including the increasing rates of colorectal cancer incidence, the enhancement of diagnostic laboratory infrastructure, the growing acceptance of molecular testing protocols, improved public understanding of early screening, and the broader application of precision medicine approaches.

The colorectal cancer molecular diagnostics market is projected to experience significant expansion in the coming years, with its size anticipated to reach $4.15 billion in 2030, advancing at a compound annual growth rate (CAGR) of 8.3%. This expected growth during the forecast period can be attributed to increased investments in precision oncology, a growing demand for minimally invasive diagnostic approaches, the expansion of genomic testing programs, the increasing integration of AI into cancer diagnostics, and a heightened focus on monitoring treatment responses. Additionally, major trends in this period include a rising adoption of molecular biomarker testing, increased use of PCR and sequencing technologies, an expanding demand for personalized oncology diagnostics, the development of more companion diagnostics, and an enhanced emphasis on early cancer detection.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13120&type=smp

What Drivers Are Shaping The Development Of The Colorectal Cancer Molecular Diagnostics Market?

The growing incidence of colorectal cancer is anticipated to drive the expansion of the colorectal cancer molecular diagnostics market moving forward. Colorectal cancer is a condition affecting parts of the digestive system, specifically the colon or rectum. It arises when cells in these areas multiply uncontrollably, forming a tumor. The increased prevalence of colorectal cancer directly boosts the demand for molecular diagnostics used in its detection and treatment. For example, in March 2023, the American Cancer Society, a US-based nationwide voluntary health organization dedicated to eliminating cancer, estimated that roughly 153,020 individuals would be diagnosed with CRC (colorectal cancer), and approximately 52,550 of them were projected to die from the disease. Among those affected, 19,550 cases and 3,750 deaths are expected to occur in individuals under the age of 50. Consequently, the rising prevalence of colorectal cancer is a significant factor propelling the growth of the colorectal cancer molecular diagnostics market.

What Segment Types Are Examined In The Colorectal Cancer Molecular Diagnostics Market?

The colorectal cancer molecular diagnostics market covered in this report is segmented –

1) By Type: Instruments, Reagents And Kits, Services

2) By Technology: Polymerase Chain Reaction (PCR), Sequencing, Mass Spectrometry, Transcription Mediated Amplification, Chips And Microarrays, Isothermal Nucleic Acid Amplification Technology (INAAT)

3) By End Users: Hospitals, Ambulatory Surgical Centers, Diagnostic Laboratories, Homecare Settings

Subsegments:

1) By Instruments: PCR Machines, Sequencers, Microarrays

2) By Reagents And Kits: DNA Or RNA Extraction Kits, Assay Kits, Reagent Packs

3) By Services: Diagnostic Testing Services, Genetic Testing Services, Consultation Services

How Are Emerging Trends Affecting The Progression Of The Colorectal Cancer Molecular Diagnostics Market?

Leading companies in the colorectal cancer molecular diagnostics market are prioritizing the creation of innovative solutions, such as blood-based liquid biopsy screening tests, to satisfy the growing need for non-invasive, early detection instruments, improved patient cooperation compared to colonoscopy, and broader population screening as guidelines and reimbursement evolve. A liquid biopsy is a blood test designed to identify tumour-derived biomarkers from a simple blood draw; its core characteristics include minimal invasiveness, the capacity to screen asymptomatic populations, and complementary molecular-level sensitivity. For instance, in July 2024, Guardant Health, a United States-based precision oncology company, introduced Shield, a blood-based colorectal cancer screening test that received approval from the U.S. Food and Drug Administration as a primary screening option for average-risk adults 45 and older. Shield functions as a multi-marker blood assay, analyzing circulating tumour signals to identify individuals likely to have colorectal cancer; it was developed and validated within the extensive ECLIPSE clinical programme and demonstrated high sensitivity and specificity adequate for FDA primary-screening designation. The test’s composition and operational mechanism combine sequencing and proprietary bioinformatic classifiers to detect methylation and other tumour-derived signals in plasma. Its unique attributes include convenience (a single blood draw), the potential to boost screening participation, and a pathway to Medicare coverage, with its applications spanning population screening and guiding positive cases to diagnostic colonoscopy, thereby offering earlier detection with fewer invasive procedures.

Who Are The Top-Performing Companies In The Colorectal Cancer Molecular Diagnostics Market In Recent Years?

Major companies operating in the colorectal cancer molecular diagnostics market are Johnson & Johnson, Bayer AG, Abbott Laboratories, Danaher Corporation, Becton Dickinson and Company, Biocartis Group NV, Agilent Technologies Inc., Grifols S.A, Hologic Inc., Biomérieux SA, Quidel Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Illumina Inc., Cepheid, Myriad Genetics Inc., Guardant Health, Luminex Corporation, GenMark Diagnostics, Amoy Diagnostics Co. Ltd., MDxHealth Inc., HTG Molecular Diagnostics Inc., GenPath Diagnostics, geneOmbio Technologies Pvt.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-molecular-diagnostics-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Colorectal Cancer Molecular Diagnostics Market?

North America was the largest region in the colorectal cancer molecular diagnostics market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the colorectal cancer molecular diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Colorectal Cancer Molecular Diagnostics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13120&type=smp

Browse Through More Reports Similar to the Global Colorectal Cancer Molecular Diagnostics Market 2026, By The Business Research Company

Pancreatic Cancer Diagnostic Market Report 2026

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-diagnostic-global-market-report

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Colorectal Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795